AB 782 California Assembly · 2023-2024 Regular Session

Pharmacies: compounding.

Summary
Existing law, the Pharmacy Law, requires the California State Board of Pharmacy to license and regulate the practice of pharmacy by pharmacists and pharmacy corporations in this state. Existing law prohibits a pharmacy from compounding sterile drug products unless the pharmacy has obtained a sterile compounding pharmacy license from the board. Existing law requires the compounding of drug preparations by a pharmacy for furnishing, distribution, or use to be consistent with standards established in the pharmacy compounding chapters of the current version of the United States Pharmacopeia-National Formulary, including relevant testing and quality assurance. Existing law authorizes the board to adopt regulations to impose additional standards for compounding drug preparations. This bill would, notwithstanding those provisions, specify that compounding does not include reconstitution of a drug pursuant to a manufacturer's directions, the sole act of tablet splitting or crushing, capsule opening, or the addition of a flavoring agent to enhance palatability. The bill would require a pharmacy to retain documentation that a flavoring agent was added to a prescription and to make that documentation available to the board or its agent upon request.
Bill status vetoed 4 of 5 stages cleared
Introduction
Feb 2023
Committee Review
Sep 2023
Assembly Passage
Mar 2023
Senate Passage
Sep 2023
Vetoed
Jan 2024
Introduced Feb 13, 2023 Vetoed Jan 3, 2024
Floor votes · Senate Sep 6, 2023 · Assembly Mar 30, 2023

How they voted

400
Passed
Total votes 40
Sep 6, 2023
D Democratic31
31 Yea
100% Yea
R Republican9
9 Yea
100% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
34
Key actions
11
Committee
12
Amendments
5
Jan 29, 2024
Vetoed
Consideration of Governor's veto stricken from file.
lower
Jan 3, 2024
Vetoed
Consideration of Governor's veto pending.
lower
Oct 8, 2023
Vetoed
Vetoed by Governor.
lower
Sep 14, 2023
Lower · Passed
Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 79. Noes 0. Page 3532.).
lower
Sep 13, 2023
Lower · Passed
From committee: That the Senate amendments be concurred in. (Ayes 19. Noes 0.) (September 13).
lower
Sep 7, 2023
Committee
Re-referred to Com. on B. & P. pursuant to Assembly Rule 77.2.
lower
Sep 6, 2023
Introduced
In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 8 pursuant to Assembly Rule 77.
lower
Sep 6, 2023
Upper · Passed
Read third time. Passed. Ordered to the Assembly. (Ayes 40. Noes 0. Page 2397.).
upper
Aug 28, 2023
Upper · Passed
From committee: Be ordered to second reading pursuant to Senate Rule 28.8.
upper
Aug 21, 2023
Introduced
From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on APPR.
upper
Aug 2, 2023
Upper · Passed
In committee: Hearing postponed by committee.
upper
Jul 10, 2023
Upper · Passed
From committee: Do pass and re-refer to Com. on APPR. (Ayes 13. Noes 0.) (July 10). Re-referred to Com. on APPR.
upper
Jun 27, 2023
Introduced
From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E. D.
upper
Jun 22, 2023
Committee
Re-referred to Com. on B., P. & E. D.
upper
Jun 22, 2023
Committee
Re-referred to Com. on RLS pursuant to Senate Rule 29.10c.
upper
Jun 19, 2023
Upper · Passed
Read second time and amended. Ordered returned to second reading.
upper
Jun 13, 2023
Upper · Passed
From committee: Do pass. To Consent Calendar. (Ayes 14. Noes 0.) (June 13).
upper
May 3, 2023
Committee
Referred to Com. on G.O.
upper
Mar 30, 2023
Lower · Passed
Read third time. Passed. Ordered to the Senate. (Ayes 65. Noes 0. Page 1008.)
lower
Mar 22, 2023
Lower · Passed
From committee: Do pass. To Consent Calendar. (Ayes 20. Noes 0.) (March 22).
lower
Feb 23, 2023
Committee
Referred to Com. on G.O.
lower
Feb 14, 2023
Lower · Passed
From printer. May be heard in committee March 16.
lower
1 primary · 2 co-sponsors

Sponsors